Abstract. The behavior of 26 male cats was systematically observed during, and after daily administration of the tryptophan hydroxylase it p-chlorophenylalanine. These observations established that "hypersexuali creased aggression, and perceptual disorientation are sequelae of the administration of the drug in cats.
following numbers on the ordinate observed for sexual activity; 1, r action, ignores other cat; 2, snif cat casually; 3, grooms its own ge: grooms other cat anywhere; 5, sexual cry; 6 pursues other cat, sr 7, tries to mount but is easily discl 8, mounts in an integrated delibern ner; and 9, mounts reflexly, all voluntarily, in a stereotyped fashic gories 1 to 4 are normal pattern havior among cats; 5 and 6 are inary sexual maneuvers; and 7 t overt sexual acts. Category 10 (v to mount or stay mounted) was in this cat. On some days more t observation was made.
modified by the variation in PCPA dosage among the group B animals. Of the constellation of emergent behavioral changes, the appearance of "hyperbefore, sexuality" was perhaps the most draihibitor, matic. By "hypersexuality," we mean ty," in-the marked tendency of one male cat chronic to mount and attempt intercourse with another male cat (5). Although homosexual behavior has been occasionally day to reported in presumably normal cats (6), cats in under the conditions prevailing in our reas the laboratories over the past several years ged becountless opportunities for such intercats in actions among male cats have produced )ur-long only one or two undocumented infirst 9 stances of mounting. These many opnumber portunities have included specific test between situations similar to those used in the )mbined study reported here (7). periods There is a fairly definite and easily 1 to the graded sequence of behaviors which otations constitute a complete sexual act for the ersonnel cat (see Fig. 1 A third category of changes seemed to involve perceptual processes. Their complexity and individuality resisted simple description and quantification. Every animal receiving PCPA showed a variety of perceptual disturbances, the development of which was consistently related to the time course of the drug. In general the first change was an episode of prolonged wakefulness which usually occurred at around 50 to 60 hours after the first PCPA injection. The animals moved around restlessly in their cages, and even when they were crouched in one place they constantly shifted their weight from one side to the other. In the observation room they ceaselessly explored, sniffing and looking at each object many times. After this period of hyperactivity was well established, episodes of unusual perceptual behavior began to occur. At first the animals seemed to overreact to slight noises, and occasionally they looked wildly around the room when a single moving stimulus such as a rat was present. They often stared at a fixed point for long intervals. Eventually all of the cats showed episodes of looking around the room as though they were watching some obscure object moving in the air. Precautions were taken to assure that the cats were not, in fact, watching something real (for example, a fly). Rapid darting eye movements, orienting movements of the ears, and extensive sniffing often accompanied this visual searching. The extreme of these perceptual disturbances was seen in two-thirds of the cases when animals appeared to interact emotionally with stimuli not apparent to the observer. The animals were observed to hiss and back into a corner in a typical fear response, to strike out at unseen objects, and even to interrupt ongoing activity such as mounting another animal to attend to nonexistent stimuli. Eight cats were studied during the period of recovery from the drug treatment (10). Fifteen days after treatment with PCPA was discontinued, this group of animals no longer exhibited unusual behavior patterns. Although systematic observations were not continued beyond this point, we felt that the animals' subsequent behavior was essentially normal.
Nearly all the cats studied showed marked alterations in sexual, aggressive, and perceptual behaviors during chronic administration of PCPA, and all animals were definitely changed by the drug in one or more of these categories of behavior. In addition, all animals suffered a reduction in total amount of sleep (11). These findings of totally altered behavioral patterns in cats are in marked contrast with the paucity of behavioral consequences of PCPA treatment reported in earlier investigations (2, 3). However, a recent report on the effects of PCPA in rats has documented simultaneous enhancement of sexual, aggressive, and grooming behaviors (12) . Augmentation of sexual behavior in rats treated with PCPA has been confirmed (13), and incidental observation of mouse-killing tendencies in rats treated with PCPA presumably confirms the enhancement of aggressive behavior (14) .
In all of this work it would appear that the behavioral response to PCPA administration is more intense and more enduring and involves more specific modalities of behavior in the cat than in the rat. The same applies to the effect of PCPA on sleep patterns in the rat where the reported changes range from moderate changes to none at all (15). However, before one concludes that a profound and encompassing behavioral effect of PCPA administration is unique to the cat, further studies with long-term administration of PCPA at several concentrations and continuous observation of many behavioral modalities in the rat should be done. It is possible that discrepancies in the response to PCPA across species would be reflected in differential changes in other compounds during PCPA administration (16).
It is worth noting that the behavioral changes associated with long-term PCPA administration are provocatively similar to the changes associated with prolonged selective deprivation of rapid eye movement (REM) sleep in both cats (7, 17) and rats (18), although the effects of the manipulation of REM sleep are somewhat less intense. Furthermore, the administration of amphetamine to rats deprived of REM sleep intensifies the syndrome to the point where compulsive mounting and aggressive posturing occur spontaneously (19) . Finally, the above-mentioned behavior of rats given amphetamine and deprived of REM sleep is identical with the behavior of rats who are treated with reserpine and then given amphetamine (19, 20 The action of rubidium on central excitability in monkeys has been described (1). The effectiveness of another alkaline earth cation, lithium, in the treatment of mania has been tentatively associated with the effect of this ion on brain amine metabolism (2) which is perhaps related to an interaction with other cations intimately involved in adrenergic neurotransmission. In contrast to the effects of lithium in both humans and infrahuman species, rubidium causes hyperactivity, increased aggressiveness, and electroencephalographic activation. We examined the effects of short-term rubidium treatment on gross behavior and on the metabolism of brain catecholamines in rats.
Our experiments were performed on male Long-Evans rats that weighed 250 to 300 g at the start of the study. The rats, housed in groups of four, were injected daily with saline or with rubidium chloride (0.6 meq per kilogram of body weight; intraperitoneally) for ten consecutive days. Twenty-four hours after the last injection, groups (n = 16) of both the control rats and those treated with rubidium were into central adrenergic receptors.
The action of rubidium on central excitability in monkeys has been described (1). The effectiveness of another alkaline earth cation, lithium, in the treatment of mania has been tentatively associated with the effect of this ion on brain amine metabolism (2) which is perhaps related to an interaction with other cations intimately involved in adrenergic neurotransmission. In contrast to the effects of lithium in both humans and infrahuman species, rubidium causes hyperactivity, increased aggressiveness, and electroencephalographic activation. We examined the effects of short-term rubidium treatment on gross behavior and on the metabolism of brain catecholamines in rats.
Our experiments were performed on male Long-Evans rats that weighed 250 to 300 g at the start of the study. The rats, housed in groups of four, were injected daily with saline or with rubidium chloride (0.6 meq per kilogram of body weight; intraperitoneally) for ten consecutive days. Twenty-four hours after the last injection, groups (n = 16) of both the control rats and those treated with rubidium were in- Brains were dissected into stem (comprising diencephalon, metencephalon, and myelencephalon) and telencephalon fractions for amine determination. After the fractions were homogenized in 0.4N perchloric acid, the supernatants were adjusted to pH 6.5 and passed over IRC-50 resin. Norepinephrine (NE), dopamine (DA), and 5-hydroxytryptamine (serotonin, 5-HT) were assayed spectrophotofluorimetrically after elution from the resin by 0.5N acetic acid. Values for brain NE and DA concentrations were subjected to regression analysis by least-square fitting to obtain rate constants for their disappearance after inhibition of catecholamine biosynthesis.
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